Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutant p53 such as APR-246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933).
